Loading
RenovoRx, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing therapies for solid tumor malignancies. The company's primary investigational therapy, RenovoGem, is an innovative drug and device combination. It integrates intra-arterial gemcitabine with the RenovoCath system, currently progressing through pivotal Phase III clinical trials for the treatment of locally advanced pancreatic cancer. Established in 2009, RenovoRx, Inc. maintains its headquarters in Los Altos, California.
Previous close
$1.77
−$0.225 · -11.28%
After-hours
$1.81
+$0.04 · +2.26%
Sep 10, 7:56 PM ET
Regular session · ET · Market data may be delayed.
RenovoRx, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing therapies for solid tumor malignancies. The company's primary investigational therapy, RenovoGem, is an innovative drug and device combination. It integrates intra-arterial gemcitabine with the RenovoCath system, currently progressing through pivotal Phase III clinical trials for the treatment of locally advanced pancreatic cancer. Established in 2009, RenovoRx, Inc. maintains its headquarters in Los Altos, California.
Day range
Current $1.77
52-week range
Current $1.77
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
72
Undervalued
Sentiment
62
Bullish
Risk
64
High Risk
Momentum
39
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
RenovoRx, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing therapies for solid tumor malignancies. The company's primary investigational therapy, RenovoGem, is an innovative drug and device combination. It integrates intra-arterial gemcitabine with the RenovoCath system, currently progressing through pivotal Phase III clinical trials for the treatment of locally advanced pancreatic cancer. Established in 2009, RenovoRx, Inc. maintains its headquarters in Los Altos, California.
Day range
Current $1.77
52-week range
Current $1.77
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 1.12M USD | 43K USD | — | — | — |
| Cost of goods sold | 327K USD | — | — | — | — |
| Gross profit | 796K USD | 43K USD | — | — | — |
| Research and development | 6.27M USD | 6.03M USD | 5.67M USD | 4.3M USD | 3.04M USD |
| Selling, general, and administrative | 7.04M USD | 4.99M USD | 5.73M USD | 5.65M USD | 2.63M USD |
| Operating expenses | 13.31M USD | 11.01M USD | 11.4M USD | 9.95M USD | 5.67M USD |
| Interest income | 427K USD | 384K USD | — | 57K USD | 70K USD |
| Interest expense | — | — | 108K USD | 57K USD | 904K USD |
| Depreciation and amortization | 2K USD | — | 6K USD | 6K USD | 9K USD |
| Operating income | −12.51M USD | −10.97M USD | −11.4M USD | −9.95M USD | −5.67M USD |
| Net income | −11.17M USD | −8.81M USD | −10.23M USD | −9.89M USD | −6.32M USD |
Company facts updated Sep 11, 2026.
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
